Neuropathix Inc. (TYGS) Return on Investment ROI from the first quarter of 2022 to first quarter of 2021 and for the year 2022, average high and low, overall ranking from Mar 31 2022 to Mar 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Neuropathix Inc.  (TYGS)


Neuropathix's ROI from its first quarter of 2022 to the first quarter of 2021 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Neuropathix's ROI in the first quarter of 2022?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Neuropathix Inc.'s return on investment (ROI) in its first quarter of 2022

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter		 (Mar 31 2021)
I. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -3 -3 -2 -2 -2
Return On Investment (TTM) - - - - -
TYGS's Overall Ranking # # # # #
Seq. Investment Change TTM - - - - -
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -4 -4 -4 -4 -6

TYGS Company Profile >> Back to TYGS Roi Comparisons >> See Annual TYGS Return On Investment



Return On Investment TYGS's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 







Financial Statements
Neuropathix's I. Quarter Investments $ -3 Millions TYGS's Balance sheet
Neuropathix's I. Quarter Income $ -2 Millions Quarterly TYGS's Income Statement
TYGS's Income by Division See TYGS's Income by Division


TYGS Annual Return On Investment (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017
Total Investments in Millions -3 -2 -1 2 0
Y / Y Investment Growth - - - - -
Net Income in Millions -4 -5 -3 1 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment - - - 37.68 % -


Annual Roi Comment
In the fiscal year 2021 ROI improved to 37.68 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TYGS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TYGS's Competitors
Subscribers only: Roi for Neuropathix's Suppliers
Subscribers only: Return On Investment for TYGS's Customers

Other Ratios
TYGS's Roa TYGS's Inventory Turnover Ratio TYGS's Growth Rates TYGS's Dividend Statistics
TYGS's Profitability Ratios TYGS's Asset Turnover Ratio TYGS's Dividend Growth
TYGS's Roe TYGS's Valuation Ratios TYGS's Financial Strength Ratios TYGS's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2022, within Healthcare Sector ROI
Biovie Inc   169.54 %
Ir med Inc   140.85 %
Moderna Inc   112.19 %
REST EZ Inc.  99.51 %
Procept Biorobotics Corporation  98.49 %
Vyne Therapeutics Inc   95.25 %
Warby Parker Inc   90.77 %
Omeros Corporation  89.24 %
Entrada Therapeutics Inc   86.65 %
Vir Biotechnology Inc   85.55 %
Carisma Therapeutics Inc   80.40 %
Sensus Healthcare Inc   76.05 %
Lianbio  74.74 %
Glucotrack Inc   70.69 %
Effector Therapeutics Inc   63.45 %
Iteos Therapeutics Inc   62.29 %
Vivos Therapeutics Inc   61.68 %
Biomx Inc  57.01 %
Ironwood Pharmaceuticals inc   50.50 %
Molecular Templates Inc   49.08 %
Embecta Corp   47.91 %
Quidelortho Corp  47.45 %
Journey Medical Corp  46.59 %
Siga Technologies Inc  46.30 %
Avid Bioservices Inc   43.65 %
Reflect Scientific Inc  43.50 %
Halozyme Therapeutics Inc   43.26 %
Uniqure N v   42.34 %
Idexx Laboratories Inc  41.85 %
Fulgent Genetics Inc   40.69 %

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.